Skip to main content

Prokidney Corp(PROK-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low2.29
Day High2.44
Open:2.35
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

TOP STORIES: Prokidney Corp

Select a category then submit the form to load news
Tipranks
ProKidney Expands Phase 3 REGEN-006 Trial Enrollment Plans
Tipranks
ProKidney Advances Rilparencel Program and Manufacturing Expansion
GlobeNewswire
ProKidney to Present at the 44th Annual J.P. Morgan Healthcare Conference
Newswire.ca
Beyond Insulin Pumps: Cell Therapies Unlock a $403B Cure Economy
Tipranks
Bank of America Securities Keeps Their Sell Rating on ProKidney (PROK)
GlobeNewswire
ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates
GlobeNewswire
ProKidney Presents Full Results from the Phase 2 REGEN-007 Trial of Rilparencel at the American Society of Nephrology Kidney Week 2025
GlobeNewswire
ProKidney to Participate in Two Upcoming Conferences: Guggenheim Healthcare Innovation Conference and the Jefferies Global Healthcare Conference
Tipranks
Prokidney’s Long-Term Study on REACT Therapy: A Potential Game-Changer for CKD
GlobeNewswire
ProKidney Announces Two Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2025
Tipranks
ProKidney Sells Greensboro Property for $19.1 Million
Tipranks
Citi Sticks to Its Buy Rating for ProKidney (PROK)
Motley Fool
Prediction: Chamath Palihapitiya's $250 Million SPAC Could Create the Next Palantir for America's Energy Grid
Tipranks
Citi Reaffirms Their Buy Rating on ProKidney (PROK)
Tipranks
J.P. Morgan Sticks to Their Hold Rating for ProKidney (PROK)
Motley Fool
ProKidney Reports 78 Percent Gain in Q2
Motley Fool
Meet the Biotech Stock That Rocketed 775% Higher
Motley Fool
This Biotech Stock Jumped Over 600% in Just Days After Releasing Promising Clinical Trial Data. And Its Market Cap Is Still Only $2 Billion. But Is It a Buy?
Tipranks
ProKidney Secures FDA Alignment for Rilparencel Approval
Tipranks
ProKidney Enters New $200M Sale Agreement with Jefferies
Tipranks
ProKidney (PROK) Receives a Buy from Guggenheim
GlobeNewswire
ProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel
The Globe and Mail
The Globe’s stars and dogs for the week
For Stars and Dogs column in Globe Investor/ROB only.
Tipranks
ProKidney (PROK) Gets a Sell from Bank of America Securities
Tipranks
Guggenheim Reaffirms Their Buy Rating on ProKidney (PROK)
Tipranks
Citi Sticks to Its Buy Rating for ProKidney (PROK)
Zacks Investment Research
PROK Surges More Than 500% on Upbeat Data From Kidney Cell Therapy Study
PROK Surges More Than 500% on Upbeat Data From Kidney Cell Therapy Study
Tipranks
ProKidney Announces Promising Phase 2 Trial Results
Motley Fool
Stock Market Today: PROK Soars 515% on Surging Volume Amid Clinical Trial Buzz
Tipranks
ProKidney Completes Transition to Delaware Incorporation
GlobeNewswire
ProKidney Corp. Completes Domestication from the Cayman Islands to Delaware
Tipranks
Analysts Offer Insights on Healthcare Companies: MiMedx Group (MDXG), ProKidney (PROK) and Centessa Pharmaceuticals (CNTA)

Profile

ProKidney LP is a late clinical-stage cellular therapeutics company focused on CKD. The company's lead product candidate includes REACT(TM) is a first-of-its-kind, patented disease-modifying autologous cellular therapy. ProKidney LP, formerly known as Suvretta Holdings Corp. III, is based in WINSTON-SALEM, N,C.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.